Recent advances in the understanding and treatment of acute myeloid leukemia [version 1; referees: 3 approved]

by Justin Watts, Stephen Nimer
Published 2018-08-01

The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions

by Sunil Girish Iyer, Sunil Girish Iyer, Laila Elias, Michele Stanchina, Michele Stanchina, Justin Watts, Justin Watts
Published 2023-01-01

CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients

by Fatih M. Uckun, Fatih M. Uckun, Justin Watts
Published 2021-09-01

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products

by Nina Nguyen, Ellen Madarang, Alvaro Alencar, Justin Watts, Terrence Bradley
Published 2022-01-01

Methotrexate-Induced Subacute Combined Degeneration in Acute Lymphoblastic Leukemia with CNS Relapse May Be Reversible

by David Bared Dukenik, Deborah Soong, Wenhui Li, Ellen Madarang, Justin Watts, Justin Taylor
Published 2023-10-01

Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients

by Jessica L. Dennison, Hassan Al-Ali, Claude-Henry Volmar, Shaun Brothers, Justin Watts, Claes Wahlestedt, Ines Lohse
Published 2022-08-01

Spontaneous remission of acute myeloid leukemia with NF1 alteration

by Terrence Bradley, Radames Adamo Zuquello, Luis E. Aguirre, MD, Nicholas Mackrides, Jennifer Chapman, Luisa Cimmino, Amber Thomassen, Justin Watts
Published 2020-01-01

Molecular characteristics and outcomes in Hispanic and non‐Hispanic patients with acute myeloid leukemia

by Terrence Bradley, Deukwoo Kwon, Jorge Monge, Mikkael Sekeres, Namrata Chandhok, Amber Thomassen, Ronan Swords, Eric Padron, Jeff Lancet, Chetasi Talati, Justin Watts
Published 2022-11-01

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

by Fatih M. Uckun, Justin Watts, Alice S. Mims, Prapti Patel, Eunice Wang, Paul J. Shami, Elizabeth Cull, Cynthia Lee, Christopher R. Cogle, Tara L. Lin
Published 2021-10-01

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

by Fatih M. Uckun, Tara L. Lin, Alice S. Mims, Prapti Patel, Cynthia Lee, Anoush Shahidzadeh, Paul J. Shami, Elizabeth Cull, Christopher R. Cogle, Justin Watts
Published 2021-08-01

Correction to: Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia

by Bhuwan Giri, Vineet K. Gupta, Brianna Yaffe, Shrey Modi, Pooja Roy, Vrishketan Sethi, Shweta P. Lavania, Selwyn M. Vickers, Vikas Dudeja, Sulagna Banerjee, Justin Watts, Ashok Saluja
Published 2019-09-01

Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia

by Bhuwan Giri, Vineet K. Gupta, Brianna Yaffe, Shrey Modi, Pooja Roy, Vrishketan Sethi, Shweta P. Lavania, Selwyn M. Vickers, Vikas Dudeja, Sulagna Banerjee, Justin Watts, Ashok Saluja
Published 2019-05-01

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA

by Justin Watts, Tara L. Lin, Alice Mims, Prapti Patel, Cynthia Lee, Anoush Shahidzadeh, Paul Shami, Elizabeth Cull, Christopher R. Cogle, Eunice Wang, Fatih M. Uckun, Fatih M. Uckun
Published 2022-01-01